Outcomes of radiotherapy in early stage glottic laryngeal carcinoma: a single center experience

Our aim was to determine the treatment outcomes and the prognostic factors affecting local control in early stage glottic carcinoma (ESGC) treated with definitive radiotherapy (RT). Between April 2003 and May 2015, 76 patients with ESGC were treated at Inonu University Hospital. There were 58 patients with T1a, 7 T1b and 11 with T2 tumors. Twenty-two patients were treated with conformal radiotherapy, 31 patients were treated with conventional RT and 23 patients were treated with intensity modulated radiotherapy as initial treatment. During a median follow-up of 51 months (range 6-136), 11 patients had failures. Five year overall survival rates were 73.7% in T1 and 81.8% T2. Local control rate was 85.5% in our patients. Patients who were over 61 years had significantly lower local control (p = 0.042). One patient treatment was interrupted because of grade 3 edema. One patient had grade 3 dermatitis, 2 patients grade 3 mucositis and 4 patients grade 3 edema, respectively. Our results suggest that curative radiotherapy is an effective treatment modality in ESGC without increasing toxicity. Age proved to be the only independent prognostic factor affecting local control after primary radiotherapy according to the results of this study. [Med-Science 2016; 5(4.000): 928-32

Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population.

Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication

Malignancies Diagnosed During Pregnancy and Treated With Chemotherapy or Other Modalities (Review of 27 Cases) Multicenter Experiences

Background: Cancer is the second leading cause of death in women of reproductive age. The most common tumors diagnosed during pregnancy are breast and cervix cancer, Hodgkin lymphoma and non-Hodgkin lymphoma, leukemias, and malignant melanoma. The aim of therapy in pregnancy is to give optimal treatment to the mother without harm to the fetus. In the first trimester, organogenesis continues, so chemotherapy should not be given because of increasing risk of spontaneous abortion, fetal malformation, and mortality. We evaluated mostly seen tumors during pregnancy and assessed treatment type and outcome of pregnancy after chemotherapy in our population

Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology

Background: The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer. Materials and Methods: For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days). Results: Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8-20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%). Conclusions: Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients